{"entity":{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Nathalie Levasseur, not yet recruiting.","summary":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. is a phase 2, interventional study registered as NCT07299409 by Nathalie Levasseur, with a registry enrolment figure of 24 participants, started 2025-12 and due to reach its primary completion in 2027-08. Interventions recorded: Sacituzumab Govitecan (SG). Conditions listed: Advanced Triple Negative Breast Cancer; Breast Cancer Metastatic; Breast Cancer. Triple-negative eligibility wording from the registry: \"Advanced (locoregionally recurrent and non-operable, or metastatic) triple-negative breast cancer patients not amenable to curative therapy (surgery and/or radiotherapy), including those who are PDL1 negative (combined positive score \\[cps\\] \\<10), immuno-oncology therapy ineligible, or who had earl\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07299409","url":"https://clinicaltrials.gov/study/NCT07299409"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early","tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07299409","phase":"2","setting":"A Phase II Study of First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","sponsor":"Nathalie Levasseur","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07299409/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}